HiringSelective
59/100
1 relevant signal
PN
Neurotechnology · New York, United States
Precision Neuroscience
Current work outlook
Precision Neuroscience develops minimally invasive, removable brain-computer interfaces.
Updated September 24, 2026 · Evidence from public sources
Flags outlook69/ 100Positive
1 verified signal in this assessment
Why this score
Built from company events, not anonymous ratings.
The recent evidence is constructive, but the specific role and team still matter. The score weighs signal recency and source confidence. It is a decision aid—not a verdict on culture or a specific team.
StabilityMixed
60/100
1 relevant signal
Financial healthStronger
66/100
1 relevant signal
InnovationNot enough data
We need a relevant verified event before scoring this dimension.
Company timeline
What changed—and why it matters
Read events in order and look for repeated momentum or recurring risk.
Filter in all signals ↗Precision Neuroscience raises $250 million to advance commercialization of its brain interface
Precision Neuroscience has closed a $250 million Series D, bringing total capital raised to $430 million. The company says the funding will expand its clinical program, advance its Layer 7 brain-computer interface through further FDA review and build commercialization infrastructure after more than 100 patient procedures.
Employee impact
Read full analysis →The round supports a strong growth signal for neural engineering, embedded systems, clinical operations, regulatory affairs, MEMS manufacturing and commercialization roles. Candidates should account for clinical and regulatory risk and ask which positions depend on future approvals versus already funded infrastructure.